This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Inflammatory bowel disease (IBD)	Salt-inducible kinase 1 (SIK1; SIK)	<i>In vitro</i> studies suggest SIK inhibitors could help treat IBD. In mouse bone marrow-derived dendritic cells, a screen of tyrosine kinase inhibitors for compounds that induce anti-inflammatory IL-10 production identified SIK inhibition as a common mechanism engaged by hit compounds. In human macrophages and dendritic cells and in myeloid cells isolated from mouse intestines, small molecule inhibitors of SIK induced IL-10 and decreased proinflammatory cytokine production following inflammatory challenge compared with vehicle. Next steps include testing the effects of SIK inhibition on additional cell types.	Patent applications filed; available for licensing	Sundberg, T.B. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published Aug. 11, 2014; doi:10.1073/pnas.1412308111 Contact: Alykhan F. Shamji, Broad Institute of MIT and Harvard, Cambridge, Mass. e-mail: ashamji@broadinstitute.org Contact: Ramnik J. Xavier, Harvard Medical School, Boston, Mass. e-mail: xavier@molbio.mgh.harvard.edu Contact: Stuart L. Schreiber, same affiliation as above e-mail: stuart_schreiber@harvard.edu
<i>SciBX</i> 7(37); doi:10.1038/scibx.2014.1091 Published online Sept. 25, 2014				